Skip to main content

Advertisement

SpringerLink
Log in

A look ahead: future directions of SSR-directed imaging and therapy in meningioma

  • Mini - Review
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Background

Meningiomas, which are the most common of CNS tumours in adults, show a high expression of the somatostatin receptor subtype 2 (SSR). Visualization of these receptors with specific PET ligands augments contrast-enhanced MRI and CT of the brain in resolving several clinical issues related to differential diagnosis, evaluation of meningioma extent, and therapy planning or follow-up. Moreover, SSR-directed radioligands labeled with beta-emitters serve for radiopeptide therapy (RPT) in patients with recurrent or refractory meningioma. In the light of recent developments in radiochemistry, neuropathology/molecular genetics, and emerging systemic treatments, we present our perspective on future directions of SSR-directed imaging and therapy in meningioma.

Methods

We conducted a search in the PubMed literature database until June 2019 using the terms “meningioma”, “PET”, “somatostatin receptor”, “SS(T)R”, “DOTATATE”, “DOTATOC”, “radiopeptide therapy”, “imaging”, “therapy”, “classification” alone and in combination, compiled with relevant literature from the authors’ own files.

Results/conclusion

Our review identifies important emerging applications of SSR-directed imaging and therapy in patients with meningioma. We summarize the state of development novel SSR-directed radio-ligands, meningioma classifications and systemic treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I et al (2017) PET imaging in patients with meningioma—report of the RANO/PET Group. Neuro-oncology 19(12):1576–1587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE et al (2012) Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 39(9):1409–1415

    Article  PubMed  Google Scholar 

  3. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J et al (2001) PET imaging of somatostatin receptors using [68GA] DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 42(7):1053–1056

    CAS  PubMed  Google Scholar 

  4. Sommerauer M, Burkhardt J-K, Frontzek K, Rushing E, Buck A, Krayenbuehl N et al (2016) 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro-oncology 18(7):1021–1027

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Unterrainer M, Ruf V, Ilhan H, Vettermann FJ, Cyran CC, Niyazi M et al (2019) 68Ga-DOTATOC PET/CT differentiates meningioma from dural metastases. Clin Nucl Med 44(5):412–413

    Article  PubMed  Google Scholar 

  6. Al Feghali KA, Yeboa DN, Chasen B, Gule MK, Johnson JM, Chung C (2018) The use of 68Ga-DOTATATE PET/CT in the non-invasive diagnosis of optic nerve sheath meningioma: a case report. Front Oncol 8:454

    Article  PubMed  PubMed Central  Google Scholar 

  7. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A et al (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 65(1):222–227

    Article  PubMed  Google Scholar 

  8. Nyuyki F, Plotkin M, Graf R, Michel R, Steffen I, Denecke T et al (2010) Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging 37(2):310–318

    Article  PubMed  Google Scholar 

  9. Kunz WG, Jungblut LM, Kazmierczak PM, Vettermann FJ, Bollenbacher A, Tonn JC et al (2017) Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 58(10):1580–1587

    Article  CAS  PubMed  Google Scholar 

  10. Gehler B, Paulsen F, Öksüz MÖ, Hauser T-K, Eschmann SM, Bares R et al (2009) [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol 4(1):56

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Graf R, Nyuyki F, Steffen IG, Michel R, Fahdt D, Wust P et al (2013) Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys 85(1):68–73

    Article  PubMed  Google Scholar 

  12. Zollner B, Ganswindt U, Maihöfer C, Corradini S, Albert NL, Schichor C et al (2018) Recurrence pattern analysis after [68Ga]-DOTATATE-PET/CT-planned radiotherapy of high-grade meningiomas. Radiat Oncol 13(1):110

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I et al (2017) PET imaging in patients with meningioma—report of the RANO/PET Group. Neuro-Oncology. 19(12):1576–1587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E et al (2009) Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36(9):1407

    Article  CAS  PubMed  Google Scholar 

  15. Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M et al (2012) Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol 7(1):99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR et al (2015) Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med 56(2):171–176

    Article  PubMed  CAS  Google Scholar 

  17. Sabet A, Ahmadzadehfar H, Herrlinger U, Wilinek W, Biersack H-J, Ezziddin S (2011) Successful radiopeptide targeting of metastatic anaplastic meningioma: case report. Radiat Oncol 6(1):94

    Article  PubMed  PubMed Central  Google Scholar 

  18. Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N et al (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro-Oncology 18(11):1538–1547

    CAS  PubMed  PubMed Central  Google Scholar 

  19. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW et al (2006) Effects of therapy with [177Lu-DOTA0, Tyr3]Octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47(10):1599–1606

    PubMed  Google Scholar 

  20. Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D (2015) 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med 56(11):1748–1751

    Article  PubMed  CAS  Google Scholar 

  21. Backhaus P, Huss S, Kösek V, Weckesser M, Rahbar K (2018) Lung metastases of intracranial atypical meningioma diagnosed on posttherapeutic imaging after 177Lu-DOTATATE therapy. Clin Nucl Med 43(6):e184–e185

    PubMed  Google Scholar 

  22. Unterrainer M, Niyazi M, Tonn JC, Ilhan H, Bartenstein P, Albert NL (2019) Current status of SSR-directed imaging and therapy in meningioma. Clin Transl Imaging 7:171–180

    Article  Google Scholar 

  23. Werner R, Weich A, Kircher M, Solnes L, Javadi M, Higuchi T et al (2018) The theranostic promise for neuroendocrine tumors in the late 2010s-where do we stand, where do we go? Theranostics 8(22):6088–6100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M et al (2018) Safety, biodistribution, and radiation dosimetry of 68Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med 59(6):909–914

    Article  CAS  PubMed  Google Scholar 

  25. Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, Van Gent DC, Konijnenberg MW et al (2016) Comparison of the therapeutic response to treatment with a 177Lu-labeled somatostatin receptor agonist and antagonist in preclinical models. J Nucl Med 57(2):260–265

    Article  CAS  PubMed  Google Scholar 

  26. Nicolas GP, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D et al (2017) Biodistribution, pharmacokinetics, and dosimetry of 177Lu-, 90Y-, and 111In-labeled somatostatin receptor antagonist OPS201 in comparison to the agonist 177Lu-DOTATATE: the mass effect. J Nucl Med 58(9):1435–1441

    Article  CAS  PubMed  Google Scholar 

  27. Nicolas G, Baum R, Herrmann K, Lassmann M, Hicks R, Haug A et al (2017) Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours. In: UKI NETS 15th national conference, vol 52. BioScientifica

  28. Reidy DL, Pandit-Taskar N, Krebs S, O’Donoghue JA, Raj NP, Cruz E et al (2017) Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201. J Clin Oncol 35(15_suppl):4094

    Article  Google Scholar 

  29. Tian R, Jacobson O, Niu G, Kiesewetter DO, Wang Z, Zhu G et al (2018) Evans blue attachment enhances somatostatin receptor subtype-2 imaging and radiotherapy. Theranostics 8(3):735

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F et al (2018) Safety, pharmacokinetics, and dosimetry of a long-acting radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in patients with advanced metastatic neuroendocrine tumors. J Nucl Med 59(11):1699–1705

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wang H, Cheng Y, Zhang J, Zang J, Li H, Liu Q et al (2018) Response to single low-dose 177Lu-DOTA-EB-TATE treatment in patients with advanced neuroendocrine neoplasm: a prospective pilot study. Theranostics 8(12):3308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kratochwil C, Giesel F, Bruchertseifer F, Mier W, Apostolidis C, Boll R et al (2014) 213 Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 41(11):2106–2119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Šimeček J, Hermann P, Seidl C, Bruchertseifer F, Morgenstern A, Wester H-J et al (2018) Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics. EJNMMI Res 8(1):78

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM et al (2019) Molecular and translational advances in meningiomas. Neuro-oncology 21(Supplement_1):i4–i17

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H et al (2010) Genomic landscape of meningiomas. Brain Pathol 20(4):751–762

    Article  CAS  PubMed  Google Scholar 

  36. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B et al (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45(10):1134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zang K (2001) Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Genome Res 93(3–4):207–220

    Article  CAS  Google Scholar 

  38. Yuzawa S, Nishihara H, Tanaka S (2016) Genetic landscape of meningioma. Brain Tumor Pathol 33(4):237–247

    Article  CAS  PubMed  Google Scholar 

  39. Sahm F, Schrimpf D, Stichel D, Jones DT, Hielscher T, Schefzyk S et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18(5):682–694

    Article  CAS  PubMed  Google Scholar 

  40. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM et al (2016) Response assessment in neuro-oncology working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-oncology 18(9):1199–1208

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M et al (2017) Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-oncology 20(2):279–288

    Article  PubMed Central  CAS  Google Scholar 

  42. Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR et al (2018) Static and dynamic 18 F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging 45(3):443–451

    Article  CAS  PubMed  Google Scholar 

  43. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R et al (2019) Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology 21(Supplement_1):i18–i31

    Article  PubMed  PubMed Central  Google Scholar 

  44. Demetri GD, Chawla SP, Mv Mehren, Ritch P, Baker LH, Blay JY et al (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25):4188–4196

    Article  CAS  PubMed  Google Scholar 

  45. Preusser M, Spiegl-Kreinecker S, Lötsch D, Wöhrer A, Schmook M, Dieckmann K et al (2012) Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 118(20):5038–5049

    Article  CAS  PubMed  Google Scholar 

  46. Preusser M, Silvani A, Rhun EL, Soffietti R, Lombardi G, Sepúlveda JM et al (2019) Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). J Clin Oncol 37(15_suppl):2007

    Article  Google Scholar 

  47. Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray M-A et al (2015) Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6(7):4704

    Article  PubMed  Google Scholar 

  48. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM et al (2016) Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol 130(3):543–552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Chamberlain MC (2015) What constitutes activity of systemic therapy in recurrent meningioma? Neurology 85:1090

    Article  PubMed  Google Scholar 

  50. Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I et al (2019) Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology 21(1):26–36

    Article  PubMed  Google Scholar 

  51. Thakral P, Sen I, Pant V, Gupta SK, Dureja S, Kumari J et al (2018) Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). Br J Radiol 91(1091):20170172

    Article  PubMed  PubMed Central  Google Scholar 

  52. Yadav MP, Ballal S, Bal C (2019) Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res 9(1):13

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M et al (2018) An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma. Oncotarget 9(49):29082

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We acknowledge Inglewood Biomedical Editing for professional manuscript editing.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany

    M. Unterrainer, H. Ilhan, P. Bartenstein & N. L. Albert

  2. German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany

    M. Unterrainer, M. Niyazi, J. C. Tonn, P. Bartenstein & N. L. Albert

  3. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

    M. Niyazi

  4. Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany

    J. C. Tonn

Authors
  1. M. Unterrainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Niyazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. C. Tonn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Ilhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. L. Albert
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MU: conception and design of the article, drafting of the article, final approval. MN: conception and design of the article, critical revision for important intellectual content, final approval. JCT: conception and design of the article, critical revision for important intellectual content, final approval. HI: conception and design of the article, critical revision for important intellectual content, final approval. PB: conception and design of the article, critical revision for important intellectual content, final approval. NLA: conception and design of the article, critical revision for important intellectual content, final approval.

Corresponding author

Correspondence to M. Unterrainer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights statement

This article does not contain any studies with animals or human participants performed by any of the authors; therefore, the local ethics committee of the LMU Munich waived the requirement for additional approval.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Unterrainer, M., Niyazi, M., Tonn, J.C. et al. A look ahead: future directions of SSR-directed imaging and therapy in meningioma. Clin Transl Imaging 7, 357–362 (2019). https://doi.org/10.1007/s40336-019-00333-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-019-00333-4

Keywords

Search

Navigation